In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.29 up 4.03% from its previous closing price of $1.24. In other words, the price has increased by $4.03 from its previous closing price. On the day, 2.47 million shares were traded. ALLO stock price reached its highest trading level at $1.29 during the session, while it also had its lowest trading level at $1.23.
Ratios:
For a deeper understanding of Allogene Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.92 and its Current Ratio is at 8.92. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.23.
On March 14, 2025, Citizens JMP Upgraded its rating to Mkt Outperform which previously was Mkt Perform but kept the price unchanged to $5.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 10 ’25 when MESSEMER DEBORAH M. sold 36,885 shares for $1.42 per share. The transaction valued at 52,377 led to the insider holds 107,431 shares of the business.
MESSEMER DEBORAH M. bought 36,885 shares of ALLO for $52,391 on Jun 10 ’25. On Apr 21 ’25, another insider, Yoshiyama Annie, who serves as the SVP, Finance of the company, sold 9,601 shares for $1.41 each. As a result, the insider received 13,537 and left with 130,663 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 286226528 and an Enterprise Value of 100103528.
Stock Price History:
The Beta on a monthly basis for ALLO is 0.41, which has changed by -0.5222222 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, ALLO has reached a high of $3.78, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 10.26%, while the 200-Day Moving Average is calculated to be -13.59%.
Shares Statistics:
For the past three months, ALLO has traded an average of 4.09M shares per day and 3095560 over the past ten days. A total of 220.13M shares are outstanding, with a floating share count of 152.97M. Insiders hold about 31.06% of the company’s shares, while institutions hold 60.66% stake in the company. Shares short for ALLO as of 1757894400 were 20285441 with a Short Ratio of 4.96, compared to 1755216000 on 24472217. Therefore, it implies a Short% of Shares Outstanding of 20285441 and a Short% of Float of 11.04.
Earnings Estimates
. The current rating of Allogene Therapeutics Inc (ALLO) is the result of assessments by 7.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.15 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.89 and -$1.2 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.98, with 10.0 analysts recommending between -$0.55 and -$1.47.
